Abstract
The link between elevated LDL-C levels and increased risk of coronary heart disease (CHD) events is well established. The primary hypothesis of Treating to New Targets (TNT) was that reducing LDL-C levels to well below 100 mg/dL (2.6 mmol/L) in stable CHD patients with modest LDL-C elevation could yield incremental clinical benefit. This hypothesis was tested by comparing the occurrence of major cardiovascular endpoints in two groups of patients: one that received 10-mg atorvastatin daily with the intent to reach an average LDL cholesterol target of approximately 100 mg/dL (2.6 mmol/L), and one that received 80-mg atorvastatin daily with the intent to reach an average LDL cholesterol of approximately 75 mg/dL (1.9 mmol/L). The results of the TNT study indicate that the linear relationship between reduced LDL-C and reduced CHD risk demonstrated in prior statin secondary prevention trials holds true even at very low LDL-C levels.
Original language | English (US) |
---|---|
Title of host publication | Concepts, Principles, Trials, and Designs |
Publisher | wiley |
Pages | 887-893 |
Number of pages | 7 |
Volume | 1 |
ISBN (Electronic) | 9781118596005 |
ISBN (Print) | 9781118595923 |
DOIs | |
State | Published - Sep 26 2014 |
Keywords
- Coronary heart disease (CHD)
- Treating to New Targets (TNT)
ASJC Scopus subject areas
- General Medicine